ARS Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2021-03-12

Reporting Person: Koehler Maria (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-12	Stock Option (right to buy)	$55.51	A	25000	Acquired	2031-03-11	Common Stock (25000)	Direct

Footnotes

F1: The shares subject to the option shall vest in equal monthly installments over the 36 months following March 12, 2021.